Dobesil LD4%+2%+0.025%

Dobesil LD is a topical/rectal combination product indicated for the symptomatic relief of internal and external hemorrhoids and their associated symptoms.

Established uses

• Symptomatic relief of pain, burning, itching, and swelling associated with hemorrhoids (piles)
• Relief of associated anorectal inflammation and irritation
• Adjunct symptomatic care after minor anorectal procedures, when advised by a physician

Important note

Dobesil LD provides symptomatic relief only; it does not treat the underlying cause of hemorrhoids. Dietary fiber, adequate hydration, and improved bowel habits remain important complementary measures and should be continued alongside use of this product.

Each unit (cream/ointment/suppository, as per the specific formulation) of Calcium Dobesilate + Lidocaine + Dexamethasone contains:

• Calcium Dobesilate - a vascular-protective (capillary-stabilizing) agent
• Lidocaine - a local anesthetic
• Dexamethasone - a corticosteroid (anti-inflammatory agent)

Exact strengths vary by brand and formulation; refer to the specific product label for precise composition.

Dobesil LD is a fixed-dose topical/rectal combination product formulated for local (external and/or intrarectal) application in the management of hemorrhoidal disease. It combines three complementary actions:

• Calcium dobesilate reduces capillary fragility and permeability, helping to reduce venous congestion and swelling in the anorectal area.
• Lidocaine is a local anesthetic that provides rapid, temporary relief of pain, burning, and itching by reversibly blocking nerve conduction at the application site.
• Dexamethasone is a potent corticosteroid that reduces local inflammation, redness, and swelling.

Dobesil LD is intended for short-term, external/rectal topical use only, as directed by a physician.

Dobesil LD belongs to the therapeutic class of topical anorectal (anti-hemorrhoidal) preparations, combining a vascular-protective agent, a local anesthetic, and a topical corticosteroid.

Calcium Dobesilate + Lidocaine + Dexamethasone exerts its therapeutic effect through the combined pharmacological actions of its three components.

Calcium dobesilate

Reduces increased capillary permeability and fragility, decreases platelet hyperaggregability, and improves lymphatic drainage, which helps reduce venous stasis, congestion, and edema in hemorrhoidal tissue.

Lidocaine

An amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of nerve impulses, thereby producing local anesthesia and relief of pain and pruritus.

Dexamethasone

A synthetic corticosteroid that suppresses local inflammatory mediators (e.g., prostaglandins, leukotrienes), reducing vasodilation, edema, and inflammatory cell infiltration at the site of application.

Dobesil LD is for external and/or rectal topical use only. Wash and dry the affected area gently before application (for cream/ointment). For suppositories, insert after a bowel movement if possible, and wash hands before and after application. Do not apply to broken or infected skin unless directed by a physician. Not for oral, ophthalmic, or intravaginal use.

Well-verified, clinically significant drug interactions with Dobesil LD are limited given its topical/local route of administration and generally low systemic absorption when used as directed.

• Other topical anorectal products: Concurrent use of multiple anorectal preparations may increase the risk of local irritation or excessive local corticosteroid/anesthetic exposure; avoid combining with other topical corticosteroid or anesthetic products on the same area without medical advice.
• Class III antiarrhythmics (e.g., amiodarone, mexiletine): If substantial systemic absorption of lidocaine occurs (e.g., with prolonged use over large or broken mucosal areas), additive cardiac conduction effects are theoretically possible; use with caution.

Inform your physician or pharmacist of all other medicines, including topical products, that you are using.

Side effects with Dobesil LD are usually local and mild when used as directed, but may include:

• Local burning, stinging, or itching sensation at the application site
• Local skin irritation, redness, dryness, or contact dermatitis
• Rash or allergic skin reaction

Less common, generally associated with prolonged or excessive use:

• Local skin/mucosal thinning (atrophy) with prolonged corticosteroid use - see Precautions and Warnings
• Systemic effects (e.g., dizziness, numbness beyond the application site) if lidocaine is absorbed systemically in excess - see Precautions and Warnings

Discontinue use and consult a physician if a severe or persistent reaction occurs.

Data on the use of Dobesil LD during pregnancy and lactation are limited. As with other topical corticosteroid/anesthetic combinations, this product should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Use during breastfeeding should also be under medical supervision; avoid applying to the breast area if breastfeeding. Consult a physician before use if pregnant, planning pregnancy, or breastfeeding.

Observe the following precautions when using Dobesil LD:

• For external/rectal topical use only; not for oral, ophthalmic, or intravaginal use
• Limit duration of use to the period stated on the product label (typically short-term); prolonged corticosteroid use on anorectal mucosa can cause local tissue thinning, atrophy, and other steroid-related local effects
• Avoid exceeding the labeled application amount or frequency, as excessive use (particularly over irritated or extensive mucosal surface area) increases the risk of systemic lidocaine absorption
• Discontinue use and seek medical evaluation if bleeding, severe pain, or symptoms persist or worsen beyond the labeled short-term use period
• Dobesil LD does not address underlying causes of hemorrhoids; dietary fiber, adequate hydration, and bowel habit modification remain important complementary measures
• Avoid contact with the eyes; if accidental contact occurs, rinse thoroughly with water

Topical overdose or accidental ingestion of Dobesil LD is unlikely to cause serious harm when used as directed, but excessive or prolonged use may increase the risk of systemic corticosteroid or lidocaine-related effects (e.g., dizziness, drowsiness, irregular heartbeat). In case of suspected overdose or accidental ingestion, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No specific dose adjustment is generally required for Dobesil LD in elderly patients, but use with caution and monitor for local skin changes.

Renal/hepatic impairment: No well-established dose adjustment is required for topical use, as systemic absorption is minimal when used as directed; however, caution is advised with prolonged or extensive application.

Pediatric patients: See Pediatric Uses.

Pregnancy/lactation: See Pregnancy and Lactation.

Use of Dobesil LD should generally be limited to short-term treatment, typically not exceeding 7 days, unless otherwise directed by a physician. Prolonged use beyond the labeled period increases the risk of local corticosteroid-related side effects. If symptoms do not improve or worsen within this period, consult a physician for re-evaluation.

Calcium Dobesilate + Lidocaine + Dexamethasone is classified as a topical anorectal combination product comprising a vascular-protective agent (calcium dobesilate), an amide-type local anesthetic (lidocaine), and a corticosteroid (dexamethasone).

Calcium Dobesilate + Lidocaine + Dexamethasone acts through three complementary mechanisms: calcium dobesilate reduces capillary permeability and fragility to reduce venous congestion; lidocaine blocks sodium channels in nerve membranes to produce local anesthesia; and dexamethasone suppresses local inflammatory mediators to reduce swelling and inflammation.

Safety and efficacy of Dobesil LD in pediatric patients have not been well established. Use in children should only be under the direct supervision and guidance of a physician, with careful attention to the amount and duration of application due to the higher risk of systemic absorption relative to body surface area in children.